{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:38:58Z","timestamp":1768916338868,"version":"3.49.0"},"reference-count":61,"publisher":"Houston Methodist DeBakey Heart & Vascular Center","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,6]]},"DOI":"10.14797\/mdcvj.1155","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T11:43:28Z","timestamp":1670327008000},"page":"40-53","source":"Crossref","is-referenced-by-count":1,"title":["Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure"],"prefix":"10.14797","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0351-4464","authenticated-orcid":false,"given":"Khawaja M.","family":"Talha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3192-8093","authenticated-orcid":false,"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9541-6954","authenticated-orcid":false,"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-4720","authenticated-orcid":false,"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5826","reference":[{"key":"key20221206064319_B1","unstructured":"FDA.gov [Internet]. Silver Spring, MD: US Food and Drug Administration; c2022. Guidance for Industry Diabetes Mellitus \u2014Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes; 2008 Dec [cited 2022 Oct 15]. Available from: https:\/\/www.fda.gov\/media\/71297\/download"},{"issue":"9131","key":"key20221206064319_B2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"9","key":"key20221206064319_B3","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","article-title":"Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes","volume":"60","year":"2017","journal-title":"Diabetologia"},{"issue":"3","key":"key20221206064319_B4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1463-1326.2010.01349.x","article-title":"Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials","volume":"13","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"key20221206064319_B5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12933-019-0900-7","article-title":"Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis","volume":"18","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"24","key":"key20221206064319_B6","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"key20221206064319_B7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa073394","article-title":"Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis","volume":"357","year":"2007","journal-title":"N Engl J Med"},{"issue":"9681","key":"key20221206064319_B8","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","year":"2009","journal-title":"Lancet"},{"issue":"14","key":"key20221206064319_B9","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after Ischemic Stroke or Transient Ischemic Attack","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"key20221206064319_B10","first-page":"789","article-title":"A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results","volume":"19","year":"1970","journal-title":"Diabetes"},{"issue":"9131","key":"key20221206064319_B11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"4","key":"key20221206064319_B12","article-title":"The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials","volume":"13","year":"2016","journal-title":"PLoS Med"},{"issue":"10","key":"key20221206064319_B13","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/dme.12232","article-title":"Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis","volume":"30","year":"2013","journal-title":"Diabet Med"},{"issue":"5","key":"key20221206064319_B14","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2337\/dc16-1943","article-title":"Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies","volume":"40","year":"2017","journal-title":"Diabetes Care"},{"issue":"4","key":"key20221206064319_B15","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s13300-018-0443-z","article-title":"Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments","volume":"9","year":"2018","journal-title":"Diabetes Ther"},{"issue":"12","key":"key20221206064319_B16","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial","volume":"322","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"key20221206064319_B17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","year":"2009","journal-title":"N Engl J Med"},{"issue":"24","key":"key20221206064319_B18","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of Intensive Glucose Lowering in Type 2 Diabetes","volume":"358","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"key20221206064319_B19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"key20221206064319_B20","article-title":"The Association Between Baseline Insulin Treatment and Cardiovascular Events: A Meta-Analysis","volume":"5","year":"2020","journal-title":"J Endocr Soc"},{"issue":"9","key":"key20221206064319_B21","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"key20221206064319_B22","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"key20221206064319_B23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"key20221206064319_B24","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"key20221206064319_B25","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"issue":"10157","key":"key20221206064319_B26","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","year":"2018","journal-title":"Lancet"},{"issue":"10193","key":"key20221206064319_B27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"key20221206064319_B28","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"key20221206064319_B29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"key20221206064319_B30","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2022. Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes; 2022 Sep 22 [cited 2022 Oct 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04916470"},{"key":"key20221206064319_B31","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2022. Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity; 2022 Sep 22 [cited 2022 Oct 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04788511"},{"issue":"14","key":"key20221206064319_B32","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"issue":"9982","key":"key20221206064319_B33","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","year":"2015","journal-title":"Lancet"},{"issue":"14","key":"key20221206064319_B34","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"key20221206064319_B35","article-title":"A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus","volume":"16","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"key20221206064319_B36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"key20221206064319_B37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial","volume":"321","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"key20221206064319_B38","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4330\/wjc.v13.i10.585","article-title":"Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials","volume":"13","year":"2021","journal-title":"World J Cardiol"},{"issue":"22","key":"key20221206064319_B39","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"key20221206064319_B40","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"key20221206064319_B41","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"key20221206064319_B42","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"key20221206064319_B43","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"key20221206064319_B44","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis","volume":"6","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"21","key":"key20221206064319_B45","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"key20221206064319_B46","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"key20221206064319_B47","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"key20221206064319_B48","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"key20221206064319_B49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"key20221206064319_B50","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","year":"2022","journal-title":"Nat Med"},{"key":"key20221206064319_B51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ahj.2020.10.071","article-title":"Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial","volume":"232","year":"2021","journal-title":"Am Heart J"},{"key":"key20221206064319_B52","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ahj.2022.05.010","article-title":"Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial","volume":"253","year":"2022","journal-title":"Am Heart J"},{"key":"key20221206064319_B53","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2022. Dapagliflozin Effects on Cardiovascular Events in Patients With an Acute Heart Attack; 2022 Oct 17 [cited 2022 Oct 17]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04564742"},{"issue":"11","key":"key20221206064319_B54","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S2213-8587(19)30310-9","article-title":"SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?","volume":"7","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"36","key":"key20221206064319_B55","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"issue":"5","key":"key20221206064319_B56","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"key20221206064319_B57","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s13300-018-0420-6","article-title":"Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk","volume":"9","year":"2018","journal-title":"Diabetes Ther"},{"issue":"2","key":"key20221206064319_B58","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"key20221206064319_B59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"key20221206064319_B60","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","year":"2022","journal-title":"N Engl J Med"},{"key":"key20221206064319_B61","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2022. A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes; 2022 Oct 4 [cited 2022 Oct 17]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04255433"}],"container-title":["Methodist DeBakey Cardiovascular Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T11:44:24Z","timestamp":1670327064000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.houstonmethodist.org\/articles\/10.14797\/mdcvj.1155\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,12,6]]}},"alternative-id":["10.14797\/mdcvj.1155"],"URL":"https:\/\/doi.org\/10.14797\/mdcvj.1155","relation":{},"ISSN":["1947-6108"],"issn-type":[{"value":"1947-6108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}